AcelRx Pharmaceuticals Appoints Vice-President Of Commercial Strategy
This article was originally published in Scrip
AcelRx Pharmaceuticals, a company focused on acute pain, has appointed Gina Ford vice-president of commercial strategy. She has worked with the company since 2013 as consultant and was involved in the development of a commercial strategy for Zalviso (sufentanil), which is now approved in Europe. Prior to joining AcelRx, Ford ran her own consulting firm. She was also president of Accesia (a wholly owned subsidiary of Patient Services, Inc.) and has also held various leadership positions at Ipsen.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.